Philippines
HBV elimination goal
No
Year of HBV elimination goal
No data
HBV Action Plan
Out of Date
HCV elimination goal
No
Year of HCV elimination goal
No data
HCV Action Plan
Yes
Prevalence
Prevalence
Prevalence of chronic HCV (RNA+/cAg) (%)
0.58
2017
, Modelled
Ong, J.P., Lam, H. (2018). Ending the Silent Epidemic of Chronic Hepatitis in the Philippines: Establishing the Burden of Hepatitis in the Philippines. WHO Western Pacific Regional Office, Center for Disease Analysis Foundation, approved PCHRD.
Prevalence of chronic HCV (RNA+/cAg), Persons who inject drugs
No data
Mortality
Mortality
Diagnosed & treated
Proportion of persons living with HBV diagnosed (%)
11
Proportion of diagnosed persons receiving appropriate HBV treatment (%) (among those eligible)
No data
Diagnosed & treated
Proportion of persons living with HCV diagnosed (%)
No data
Proportion of diagnosed persons who have initiated HCV treatment (%)
No data
HepB newborn vaccination
Harm reduction
Number of needles-syringes per PWID per year
No data
Key policy indicators
HBV screening recommendations for pregnant women
Adopted
No patient co-pays for HBsAg testing
Adopted
Key policy indicators
National policy for harm reduction for persons who inject drugs
Not Adopted
No patient co-pays for anti-HCV testing
Not Adopted
Simplified HCV care: Non-specialists can prescribe treatment
Adopted
Year | Value | Type | Source |
---|
Equity
Indicator | Status | Notes |
---|---|---|
Decriminalization of drug use | Not Adopted |
|
National anti-discrimination law protecting persons living with hepatitis | Not Adopted |
|
National policy for adult HBV vaccination | Adopted |
|
National policy for harm reduction for persons who inject drugs | Not Adopted |
|
National policy for syringe exchange in federal prisons | Not Adopted |
|
National strategy addresses key populations | Adopted |
|
Prevention of mother-to-child transmission
Indicator | Status | Notes |
---|---|---|
Elimination of HBV mother to child transmission goal | Yes |
|
HBV screening recommendations for pregnant women | Adopted |
|
Universal HepB birth dose policy within 24 hrs of birth | Adopted |
|
Strategic information
Indicator | Status | Notes |
---|---|---|
Estimates of HBV economic burden | Not Adopted |
|
National HBV prevalence survey within last 5 years | Not Adopted |
|
Routine official reporting of HBV incidence | Not Adopted |
|
Routine official reporting of HBV mortality | Not Adopted |
|
System to monitor HBV diagnosis and treatment | Not Adopted |
|
Financing
Indicator | Status | Notes |
---|---|---|
GFTAM funds used for HBV and/or HCV testing and treatment or harm reduction | Adopted |
|
Public budget line for HBV testing and treatment | Not Adopted |
|
National planning
Indicator | Status | Notes |
---|---|---|
HBV Action Plan | Out of Date |
|
HBV elimination goal | No |
|
Screening
Indicator | Status | Notes |
---|---|---|
HBV age-based or birth-cohort screening recommendations | Not Applicable |
|
HBV risk-based screening recommendations | Adopted |
|
HBV universal screening recommendations | Partially Adopted |
|
No patient co-pays for HBsAg testing | Adopted |
|
Access to testing and medicines
Indicator | Status | Notes |
---|---|---|
Licensed point-of-care PCR testing to detect HBV | Adopted |
|
Treatment
Indicator | Status | Notes |
---|---|---|
National HBV treatment guidelines | Developed |
|
Simplified HBV care: No treatment co-pays | Not Adopted |
|
Simplified HBV care: Treatment and monitoring algorithm for primary care providers | Adopted |
|
Year | Value | Type | Source |
---|
Year | Value | Type | Source |
---|
Equity
Indicator | Status | Notes |
---|---|---|
Decriminalization of drug use | Not Adopted |
|
Decriminalization of possession of syringes and paraphernalia | Not Adopted |
|
National anti-discrimination law protecting persons living with hepatitis | Not Adopted |
|
National policy for harm reduction for persons who inject drugs | Not Adopted |
|
National policy for syringe exchange in federal prisons | Not Adopted |
|
National strategy addresses key populations | Adopted |
|
Access to testing and medicines
Indicator | Status | Notes |
---|---|---|
Eligible for HCV generic medicines | Eligible |
|
Licensed point-of-care PCR testing to detect HCV | Adopted |
|
Registration of HCV generic medicines | Adopted |
|
Registration of HCV originator medicines | Adopted |
|
Strategic information
Indicator | Status | Notes |
---|---|---|
Estimates of HCV economic burden | Not Adopted |
|
National HCV prevalence survey within last 5 years | Not Adopted |
|
Routine official reporting of HCV incidence | Not Adopted |
|
Routine official reporting of HCV mortality | Not Adopted |
|
System to monitor HCV diagnosis and treatment | Not Adopted |
|
Financing
Indicator | Status | Notes |
---|---|---|
GFTAM funds used for HBV and/or HCV testing and treatment or harm reduction | Adopted |
|
Public budget line for HCV testing and treatment | Not Adopted |
|
National planning
Indicator | Status | Notes |
---|---|---|
HCV Action Plan | Yes |
|
HCV elimination goal | No |
|
Screening
Indicator | Status | Notes |
---|---|---|
HCV age-cohort or birth-cohort screening recommendations | Not Adopted |
|
HCV risk-based screening recommendations | Adopted |
|
HCV universal screening recommendations | Not Adopted |
|
No patient co-pays for anti-HCV testing | Not Adopted |
|
Prevention of mother-to-child transmission
Indicator | Status | Notes |
---|---|---|
HCV screening recommendations for pregnant women | Adopted |
|
Treatment
Indicator | Status | Notes |
---|---|---|
National HCV treatment guidelines | Developed |
|
Simplified HCV care: Less than 2 clinic visits during treatment | Partially Adopted |
|
Simplified HCV care: No fibrosis restrictions | Adopted |
|
Simplified HCV care: No genotyping requirements | Adopted |
|
Simplified HCV care: No sobriety restrictions | Not Adopted |
|
Simplified HCV care: No treatment co-pays | Not Adopted |
|
Simplified HCV care: Non-specialists can prescribe treatment | Adopted |
|
Year | Value | Type | Source |
---|
Page last updated: 19 January 2024